Monoclonal Antibody
2-Year Rituximab Maintenance Therapy Prolongs PFS in Elderly With CLL
January 04, 2018Investigators sought to determine the efficacy of 2-year rituximab maintenance therapy in elderly patients with CLL who achieve a complete response to abbreviated FCR induction therapy.
Pertuzumab Regimen Approved for Adjuvant, Neoadjuvant Therapy in Specific Breast Cancers
December 26, 2017The US FDA approved pertuzumab in combination with trastuzumab and chemotherapy for adjuvant treatment of HER2-positive early breast cancer, and converted accelerated to full approval for the regimen as neoadjuvant therapy in certain breast cancers.
Bisphosphonates vs Denosumab: Preventing SREs in Breast Cancer With Bone Metastasis
December 07, 2017A comparison study presented at the 2017 SABCS sought to determine the effectiveness of bisphosphonates with denosumab for skeletal-related events in women with breast cancer metastases to bone.
Prolonging Survival in MM: Daratumumab vs Pomalidomide Plus Dexamethasone
December 04, 2017A head-to-head comparison investigated whether patients with multiple myeloma achieved greater prolongation in overall survival with daratumumab monotherapy or pomalidomide plus low-dose dexamethasone.
Brentuximab Vedotin Granted FDA Approval for pcALCL, Mycosis Fungoides
November 10, 2017The US FDA has granted regular approval to brentuximab vedotin (Adcetris) for pcALCL and CD30-expressing MF in adult patients who received prior systemic therapy.
A Case of Immunotherapy-Induced Myocarditis Concomitant to MG in Lung Cancer
October 23, 2017In this case, a female patient with advanced lung cancer experiences a rare episode of nivolumab-induced Herzmyasthenie, emphasizing the need to be aware of the potential for rapid myocarditis concomitant with MG in patients undergoing treatment with anti-PD-1 monoclonal antibodies.
Nivolumab Provides Better Long-Term Efficacy Compared With Docetaxel in NSCLC
October 16, 2017Two phase 3 studies reveal the clinical benefit, safety profile, and overall survival of nivolumab and docetaxel for patients with squamous and nonsquamous NSCLC.
Overall Survival in Advanced Melanoma Improved With Nivolumab, Ipilimumab Combination
September 21, 2017Overall survival was significantly prolonged in patients with advanced melanoma who were treated with nivolumab plus ipilimumab compared with either drug alone, according to results from the Checkmate 067 study.
FDA Approves Gemtuzumab Ozogamicin for CD-33 Positive Acute Myeloid Leukemia
September 18, 2017Gemtuzumab ozogamicin (Mylotarg) was granted US FDA approval for the treatment of relapsed or refractory CD-33 positive AML in patients ages 2 years and older and newly diagnosed CD-33 positive AML in adult patients.
Affect of Daratumumab on Laboratory Blood Test Results
August 22, 2017Do monoclonal antibodies other than daratumumab cause false positives in the blood antibody screen and crossmatch obtained prior to a transfusion?
Inotuzumab Ozogamicin Granted FDA Approval for Acute Lymphoblastic Leukemia
August 18, 2017Inotuzumab ozogamicin (Besponsa), an antibody-drug conjugate comprised of a monoclonal antibody that targets CD22 linked to the cytotoxic agent calicheamicin, was granted FDA approval for the treatment of R/R B-cell precursor ALL.
Value of Type and Crossmatch Prior to Daratumumab Administration
August 14, 2017If type and crossmatch is obtained before initiating treatment with daratumumab, what good would that do if a transfusion is required a month later?
Type and Crossmatch Needed Before Initiating Treatment With Daratumumab
July 11, 2017Why is a type and crossmatch needed before starting patients on treatment with daratumumab (Darzalex)?
Adding Pertuzumab to Adjuvant Therapy Is Beneficial for Some Women with Early Breast Cancer
June 20, 2017Adding a second HER2-blocker to standard care therapy after surgery for HER2-positive breast cancer may be modestly beneficial for some women.
Checkpoint Inhibitors Appear Safe for Pediatric Cancer Patients
June 12, 2017The medications so far show little efficacy in children with cancer, but new studies may provide clues to how to change this, pediatric oncologist says.
Pembrolizumab Use With CRT Safe in Locally Advanced HNSCC
June 09, 2017Small study also showed that pembrolizumab does not significant impair radiation or chemotherapy dosing.
Adjuvant + Neoadjuvant Pembrolizumab Safe in Patients Undergoing HNSCC Surgery
June 09, 2017Study also provides evidence supporting an anti-tumor effect associated with a single preoperative dose of pembrolizumab.
Higher-Dose Adjuvant Ipilimumab More Toxic, Does Not Improve Recurrence-Free Survival
June 05, 2017Study of patients with resected high-risk melanoma reveals higher rates of treatment-related adverse events with 10 vs 3 mg/kg.
Increased 5-Year Survival Rate Seen in NSCLC Subset Treated With Nivolumab
April 20, 2017A significantly higher 5-year survival rate was seen in a small subset of patients with NSCLC treated with nivolumab.
Adjuvant Girentuximab Not Effective for Renal Cell Carcinoma
November 01, 2016Phase 2 studies have demonstrated that girentuximab possesses activity with a manageable safety profile for patients with clear cell renal cell carcinoma; therefore, in a phase 3 trial, researchers evaluated its efficacy and safety as adjuvant monotherapy.
Blinatumomab Improves Overall Survival in Acute Lymphoblastic Leukemia
June 23, 2016Overall survival for patients with acute lymphoblastic leukemia (ALL) was nearly doubled to 7.8 months from 4.0 months by treating patients with blinatumomab compared with standard of care.
Research Shows Potential for Breast Cancer Prevention in BRCA1-Driven Tumors
June 10, 2016The drug denosumab, which blocks a bone gene, may also prevent breast cancer caused by a BRCA1 mutation. This already approved drug could be available quickly, and would be the first drug for breast cancer prevention.
Follow-up Data Confirm Pembrolizumab as Standard of Care for Advanced Melanoma
June 07, 2016Final analysis of data from the phase 3 KEYNOTE-006 presented at the ASCO 2016 Annual Meeting confirm the superiority of pembrolizumab over ipilimumab for advanced melanoma.
Pembrolizumab Demonstrates Long-Term Survival in Advanced Melanoma
June 07, 2016At 3 years, 40% of patients with advanced melanoma treated with pembrolizumab are alive regardless of whether they had been treated with ipilimumab or not, follow-up results from the KEYNOTE-001 study reported at the ASCO 2016 Annual Meeting.
Daratumumab + Bortezomib/Dexamethasone: Reduced Risk of Disease Progression Seen in Relapsed or Refractory Multiple Myeloma
June 06, 2016Adding daratumumab to bortezomib and dexamethasone was associated with a 61% reduction in risk of disease progression in patients with relapsed or refractory multiple myeloma (RRMM), according to results of the phase 3 CASTOR study presented in a plenary session at the ASCO 2016 Annual Meeting.
Daratumumab Demonstrates Encouraging Efficacy in Patients With Pretreated or Refractory Multiple Myeloma
January 22, 2016Heavily pretreated and refractory patients with multiple myeloma had encouraging efficacy results with daratumumab monotherapy.
Experimental treatment shows early promise for advanced neuroblastoma in children
May 23, 2014Tumors shrank or disappeared and disease progression was temporarily halted in 15 children with advanced neuroblastoma enrolled in a safety study of an experimental antibody.
Sign Up for Free e-newsletters
ONA Articles
- Physical Inactivity Linked With Increased Risk of Hodgkin, Non-Hodgkin Lymphoma
- Challenges for Young Adult Couples Facing a Cancer Diagnosis
- Pivot Nurse Improves Patients' Navigation Through Lung Cancer Care
- Progression-Free Survival Extended With PANEX Protocol in R/R Multiple Myeloma
- Following ACS Guidelines Shown to Improve Outcomes for Colon Cancer Survivors
- Letter-Writing Project Communicates Care Wishes to Healthcare Team, Family
- Pivot Nurse Improves Patients' Navigation Through Lung Cancer Care
- Long-term Carfilzomib May Be Safe, Effective In Relapsed Multiple Myeloma
- Palliative Sedation a Valid Option for Refractory Symptoms in End-stage Cancer
- Testicular Cancer Treatment May Increase Risk for Heart Disease in Survivors
- FDA Approves Fostamatinib for ITP After Insufficient Response to Previous Treatment
- Elderly Patients Are Underrepresented in Trials For Soft Tissue Sarcoma
- Combination Effective as First-Line Therapy in Advanced ER-Positive HER2-Negative Breast Cancer
- In Older Women With Breast Cancer QoL May Predict 10-Year Mortality
- Screening Colonoscopy Improves CRC-Related Mortality in Veterans
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
| Bone Cancer | Regimens | Drugs |
| Brain Cancer | Regimens | Drugs |
| Breast Cancer | Regimens | Drugs |
| Endocrine Cancer | Regimens | Drugs |
| Gastrointestinal Cancer | Regimens | Drugs |
| Genitourinary Cancer | Regimens | Drugs |
| Gynecologic Cancer | Regimens | Drugs |
| Head and Neck Cancer | Regimens | Drugs |
| Hematologic Cancer | Regimens | Drugs |
| Lung Cancer | Regimens | Drugs |
| Other Cancers | Regimens | |
| Rare Cancers | Regimens | |
| Skin Cancer | Regimens | Drugs |